Skip to main content
SpringerLink
Log in

AS04-HPV-16/18v good value for money in Singapore

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. human papillomavirus

  2. The study was funded by GlaxoSmithKline Biologicals SA.

Reference

  • Tay SK, et al. Cost-effectiveness of two-dose human papillomavirus vaccination in Singapore. Singapore Medical Journal : 6 Oct 2017. Available from: URL: http://doi.org/10.11622/smedj.2017085

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

AS04-HPV-16/18v good value for money in Singapore. PharmacoEcon Outcomes News 789, 9 (2017). https://doi.org/10.1007/s40274-017-4416-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-017-4416-7

Search

Navigation